Our helpline: 01924 200799 Mon, Tue, Thu 9am-4pm | Wed, Fri 9am-8pm
Photo: Jan Chlebik for the ICR
The MiNESS 20-28 study is looking at factors which might be linked to pregnancy losses between 20 and 28 weeks of pregnancy. This period includes both late second trimester miscarriages and stillbirths. The researchers have chosen to use the term ‘early stillbirth’ to cover both. MiNESS 20-28 is the short name for the Mothers Working […]
The CERM trial is investigating whether treatment with the antibiotic doxycycline before conception improves pregnancy outcomes for women with recurrent miscarriage* and chronic endometritis (inflammation of the womb lining) * In this research trial, ‘recurrent miscarriage’ means two or more early miscarriages in a row. The CERM trial is now complete, and the trial data […]
The Alife2 study is investigating whether anti-coagulant (blood-thinning) treatment reduces the risk of miscarriage in women with two or more (unexplained) miscarriages and inherited thrombophilia – a blood-clotting problem.
The MifeMiso trial is an important research study which is looking at whether a single drug treatment (misoprostol) or a combination of drug treatments (mifepristone plus misoprostol two days later) is best for the medical management of missed miscarriage.
The PRISM trial is an important research study which looked at whether progesterone could prevent miscarriage in women with early pregnancy bleeding.
The RESPONSE trial tested a new medication, called NT100, in women with unexplained repeated miscarriages.
The TABLET trial is an important research study which looked at the role of thyroid antibodies in women with unexplained miscarriage.
A clear result – Progesterone supplements in the first trimester of pregnancy do NOT improve outcomes in women with a history of unexplained recurrent miscarriages.
Sarah Bailey describes a different type of research study which is looking at trying to improve the psychological wellbeing of women who have suffered recurrent miscarriage.
The Miscarriage Association (M.A.) has been involved in a partnership to decide which areas are the highest priority for miscarriage research. The project was run by the James Lind Alliance and involved other charities, healthcare professionals and researchers, as well as the M.A.. On this page you will find a short summary of the results.
Ruth interviews Professor Arri Coomarasamy, Consultant Gynaecologist and Sub-specialist in Reproductive Medicine and Surgery at Birmingham Women’s Hospital.